Effect of procainhydrochloride on phospholipase A2 catalytic activity in sodium taurocholate-induced acute experimental pancreatitis in rats.
BACKGROUND
In human acute pancreatitis (AP) the local anaesthetic procainhydrochloride (procain-HCl) is given intravenously for pain treatment. Procain has been shown to inhibit catalytic activity of pancreatic (group I) phospholipase A2 (PLA2) and non-pancreatic (group II) PLA2. Both enzymes are important mediators for the local and systemic inflammatory process in AP. To determine the effect of procain, we examined serum and tissue levels of both types of PLA2 activity in the experimental rodent taurocholate model of AP.


METHODS
In 60 rats, severe pancreatitis was induced by taurocholate. Forty rats were treated with procain-HCl intravenously at a dosage of 2 mg/kg body weight/h either at or 1 h after induction of pancreatitis. Twenty rats served as controls. We measured catalytic activities of group I and group II PLA2 in serum and tissue samples of lung and pancreas.


RESULTS
Serum group II PLA2 catalytic activity was significantly reduced 3 and 6 h after AP induction in rats treated with procain-HCl (p < 0.001) in both treatment groups. In pancreatic and lung tissue, group II PLA2 catalytic activity was significantly reduced compared with normal values (p < 0.001).


CONCLUSIONS
Procain-HCl given intravenously either at or 1 h after induction of necrotizing pancreatitis significantly inhibits group II PLA2 catalytic activity in serum and tissues.
Kahl
S
S
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University of Magdeburg, Magdeburg, Germany. s.kahl@drk-kliniken-berlin.de
Mayer
J
J
Schuette
K
K
Peuravuori
H
H
Pross
M
M
Schulz
H U
HU
Nevalainen
T J
TJ
Malfertheiner
P
P
D000818:Animals; D055162:Biocatalysis / Q000187:drug effects*; D054501:Group II Phospholipases A2 / Q000097:blood; D008168:Lung / Q000187:drug effects / Q000201:enzymology; D008297:Male; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology*; D054467:Phospholipases A2 / Q000097:blood / Q000378:metabolism*; D011343:Procaine / Q000494:pharmacology* / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013656:Taurocholic Acid
D011343:Procaine; D013656:Taurocholic Acid; D054501:Group II Phospholipases A2; D054467:Phospholipases A2